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Abstracts A69
Annual direct costs were calculated (by third-party payer perspective) for privately-
insured (n  4,764) and Medicare (n  48,742; medical costs only) beneﬁ ciaries. Indi-
rect costs were calculated for privately-insured employees with disability data (n 
1148). Costs were reported in 2006 dollars. RESULTS: In Medicare, mean medical
costs per non-vertebral, non-hip (NVNH) fracture patient were $7,463 in excess of 
controls ($13,720 vs. $6,258; p  0.01).The most expensive patients had fractures of 
the hip, multiple sites, and femur (excess costs of $25,120; $20,049; $19,213, respec-
tively). Aggregate annual excess medical costs of these NVNH patients (n  35,933)
were $268.1 million versus $200.9 million for hip fracture patients (n  7,997)
(excludes patients with hip and NVNH on index date). In the privately-insured popu-
lation, excess mean direct costs per NVNH fracture patient were $5,381 ($11,090 vs.
$5,709; p  0.01). The most expensive patients had fractures of the hip, multiple sites, 
and pelvis (excess costs of $13,801; $9,642; and $8,164, respectively). Aggregate
annual excess direct costs of these NVNH patients (n  4478) were $24.1 million 
versus $3.5 million for hip fracture patients (n  255). Mean excess indirect costs per
NV employee were $1956 ($4,349 vs. $2393; p  0.01). CONCLUSIONS: Excess 
direct and indirect costs of NV osteoporotic fracture patients to payers are substantial.
While hip fracture patients are more costly per patient, NVNH fracture patients are
associated with a larger percentage of fractures and aggregate excess costs for both 
these privately-insured and Medicare samples.
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OBJECTIVES: To evaluate the effect of golimumab (GLM) on time lost from work 
in patients with rheumatoid arthritis (RA). METHODS: The effect of GLM on time 
lost from work (days) was prospectively evaluated in 3 multicenter, randomized,
double-blind, placebo-controlled studies in patients with RA. Pooled data from 
patients receiving any injection of study agent (GLM or placebo) with or without 
methotrexate (MTX) in 3 RA studies (GO-BEFORE, GO-FORWARD, and GO-
AFTER) were included. GLM SC injections of 50 or 100 mg were administered q4 
weeks. Time lost from work for patients was collected through a questionnaire at 
baseline and q8 weeks through week 24 and was summarized cumulatively through 
week 24 with comparisons between groups using ANOVA on van der Waerden normal 
scores. The proportion of patients reporting no time lost from work in the GLM /
MTX group was compared with the PBO / MTX group using the chi square test.
RESULTS: Through week 24, signiﬁ cant differences in time lost from work were 
observed between the GLM / MTX group and the PBO / MTX group. At week 
24, the PBO / MTX group lost 6.9 o 19.7 days compared with 5.0 o 19.4 days for
the combined GLM /MTX group. At week 24, the 75th percentile for the combined 
GLM /MTX group was 1.000 day (range 0–180) compared with 3.000 days (range
0–120) for the PBO / MTX group. A signiﬁ cantly higher proportion of patients in 
the combined GLM / MTX group reported no time lost from work compared with
the PBO / MTX group (73.1% vs. 60.7%; p  0.002). CONCLUSIONS: GLM /
MTX signiﬁ cantly reduced time lost from work for patients with RA compared with 
PBO / MTX.
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OBJECTIVES: Previous research reported the prevalence and health care and
productivity cost of rheumatoid arthritis (RA) using Medical Expenditure Panel
Survey (MEPS) 2004 data; this study replicates the analyses using 2005 and 2006 
data. METHODS: MEPS, a comprehensive survey of approximately 35,000 individu-
als in the US, was used to identify non-institutionalized US persons with RA. Multiple 
linear and semi-log regressions were applied to estimate total annual health care
expenditure and income (yearly wages) associated with RA. Covariates in the expen-
diture equations included demography, comorbidities, and overall health status.
Semi-log regression for income renders the distribution of income symmetric. Covari-
ates in the income equations included demography, comorbidities, education, occupa-
tion, and health status. RESULTS: A total of 150 and 148 patients with RA were 
identiﬁ ed in 2005 and 2006 versus 136 in 2004; 75% (2005) and 80% (2006) were 
women versus 76% (2004), and 53% (2005) and 50% (2006) of RA patients 
were between the ages 41–64 years versus 56% in 2004. Linear regressions demon-
strated that the incremental increase in health care cost associated with RA was
$2902 (P  0.0001) in 2005 and $1882 (P  0.003) in 2006, versus $4422 (2004). 
Semi-logarithmic regression explaining wages in 2005 and 2006 had adjusted R2 of 
56% and 59%. RA signiﬁ cantly reduced wages by $2207 (0.9237 log estimate)
annually (P  0.0001) in 2005 and $1,559 (0.5038 log estimate; P  0.05) in 2006; 
wages of RA patients in 2004 were reduced by $3526 (1.088 log estimate). CON-
CLUSIONS: The economic impact of RA is substantial to both income loss and health 
care costs. Replication and validation of outcomes research are important to establish
the precision of statistical associations as well as changes across time. Further study
will explore whether changes in the care of patients with RA affect changes in out-
comes over time.
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OBJECTIVES: Fibromyalgia syndrome (FMS) is a chronic disorder deﬁ ned by wide-
spread musculo-skeletal pain that is often associated with a number of comorbidities 
including fatigue, sleep disturbance, stiffness and functional limitation. In absence of 
a speciﬁ c diagnostic test, FMS is typically difﬁ cult to identify, and there is limited 
knowledge about the economic burden of FMS. The objectives of this study were to
estimate prevalence of comorbidities, health care resources utilization and costs associ-
ated with FMS. METHODS: A retrospective cohort study was conducted using data 
from the Quebec provincial health plan (RAMQ) for a random sample of patients
with two or more recorded diagnoses of FMS and a control cohort without FMS,
matched for age and gender, for a period spanning from June 2006 to July 2007. 
Prevalence of comorbidities was estimated and a chronic disease score was calculated.
Health care resources consumed by FMS and non-FMS patients included visits to 
physicians, physician’s interventions, pain-related medications, non-pain-related medi-
cations and hospitalizations. RESULTS: A total of 16,010 FMS patients were identi-
ﬁ ed, with a matched number of control patients. The mean age of the study population 
was 58.8 years and most subjects were women (67.8%). The prevalence of most
comorbidities and the chronic disease score were signiﬁ cantly greater in the FMS 
patients than in control group (3.8 vs. 2.8; p  0.001). Health resources utilization
during the study period was signiﬁ cantly greater among FMS patients than non-FMS 
patients: the annual number of physician visits and interventions was 25.1 for FMS
vs. 14.8 for non-FMS patients. The amount paid by the RAMQ was signiﬁ cantly
greater for patients with FMS ($4065) compared to patients without FMS ($2766, 
p  0.001). CONCLUSIONS: This analysis of the RAMQ database indicated that
comorbidities are highly prevalent in FMS patients, and suggested that the economic 
burden associated with FMS is substantial.
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OBJECTIVES: To evaluate the relationship between out-of-pocket (OOP) pharmacy
expenses and switching rates among anti-tumor necrosis factor (anti-TNF) agents in 
patients with rheumatoid arthritis (RA). METHODS: This retrospective study utilized 
claims for RA patients from the PharMetrics Patient Centric database. The index 
biologic date was deﬁ ned as the ﬁ rst anti-TNF claim between January 1, 2000 and 
December 31, 2006. A minimum of 30 months of continuous plan eligibility was 
required: 6 months prior to and 24 months following the index biologic date. Patients
were followed for 24 months after the index biologic date. Switching among anti-
TNFs (inﬂ iximab, etanercept, or adalimumab) was recorded. The pharmacy OOP 
expense was deﬁ ned as the allowed amount minus amount paid. The annual OOP of 
$500 was used as a cut point to deﬁ ne the high and low OOP groups. RESULTS: A
total of 3,086 patients were analyzed (74.5% female; mean age  49.9 years). Half 
(1597; 51.7%) had an annual pharmacy OOP $500. The mean and median annual 
OOP expenses for the study population were $929 and $528, respectively. During the 
study period, 465 (15.1%) patients switched to a different anti-TNF agent. Compared 
to the lower OOP expense group, patients in the higher OOP group had a higher 
switching rate (18.0% versus 12.0%, p  0.0001), and shorter time to switch (329
days versus 352 days, p  0.230). In the logistic regression, after controlling for age, 
gender, co-morbidity, and disease staging, patients in the high OOP group had signiﬁ -
cantly higher switching rate (odds ratio 1.60, 95% conﬁ dence interval 1.30–1.96).
CONCLUSIONS: Higher OOP expenses were associated with higher rates of switch-
ing among the anti-TNF agents in the RA patient population. Decision makers may 
consider such ﬁ ndings in the beneﬁ t design of this therapeutic class.
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OBJECTIVES: The purpose of this study was to estimate the expected medical cost
of a single conservative medical management (CMM) per patient with osteoporotic 
vertebral compression fracture (VCF) in Japan. METHODS: A questionnaire survey
was conducted for Japanese orthopedic surgeons who mainly provide CMM for 
patients with VCF during their daily clinical practices, and who consented to
participating in the survey. Responses to the questionnaire were summarized and
the expected medical costs for each therapeutic regimen until recovery per patient
